(Q36845108)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

type 2 diabetes

9 December 2023

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Lucie Šedová

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Ondørej Seda

series ordinal

1

1 reference

16 August 2017

Lucie Sedová

series ordinal

2

1 reference

16 August 2017

publication date

1 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

587-596

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559348%20AND%20SRC:MED&resulttype=core&format=json

Understanding and addressing the epidemic of obesity: an energy balance perspective

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Dynamic genetic architecture of metabolic syndrome attributes in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Polymorphisms in CYP-7A1, not APOE, influence the change in plasma lipids in response to population dietary change in an 8 year follow-up; results from the Czech MONICA study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Application of nutrigenomic concepts to Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

PPAR gamma and human metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

PPARs and the complex journey to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Relationships between the functional PPARalpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Evidence of differing genotypic effects of PPARalpha in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Sequence variation in PPARG may underlie differential response to troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Bone is a target for the antidiabetic compound rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Pharmacogenetics and drug development: the path to safer and more effective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Gene-lifestyle interaction on risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Sucrose feeding during pregnancy and lactation elicits distinct metabolic response in offspring of an inbred genetic model of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on insulin sensitivity and insulin metabolism interact with size at birth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Interactions between peroxisome proliferator-activated receptor-gamma 2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Quantitative founder-effect analysis of French Canadian families identifies specific loci contributing to metabolic phenotypes of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Physiogenomic resources for rat models of heart, lung and blood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

A Possible Role for the PPARG Pro12Ala Polymorphism in Preterm Birth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

The Collaborative Cross, a community resource for the genetic analysis of complex traits

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

Low-intensity exercise increases skeletal muscle protein expression of PPARδ and UCP3 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

The Effects of the Pro12Ala Polymorphism of the Peroxisome Proliferator-Activated Receptor- 2 Gene on Glucose/Insulin Metabolism Interact With Prenatal Exposure to Famine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.6.587

21 January 2018

Identifiers

DOI

10.2217/14622416.8.6.587

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17559348%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference